[{"id":"af7d23ec-b13e-4076-9480-1b329c34d370","acronym":"DelVIN","url":"https://clinicaltrials.gov/study/NCT05717621","created_at":"2023-02-08T17:00:09.181Z","updated_at":"2025-02-25T15:27:53.533Z","phase":"Phase 1","brief_title":"Clinical Trial With Local Decitabine Treatment of HPV-Induced VIN Grade 2/3 (DelVIN)","source_id_and_acronym":"NCT05717621 - DelVIN","lead_sponsor":"ViMREX GmbH","biomarkers":" CDKN2A","pipe":" | ","alterations":" CDKN2A overexpression","tags":["CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 03/28/2023","start_date":" 03/28/2023","primary_txt":" Primary completion: 01/17/2025","primary_completion_date":" 01/17/2025","study_txt":" Completion: 01/17/2025","study_completion_date":" 01/17/2025","last_update_posted":"2025-02-11"}]